| ²é¿´: 1108 | »Ø¸´: 4 | |||
maryrayͳæ (³õÈëÎÄ̳)
|
[½»Á÷]
¡¾ÌÖÂÛ¡¿FDA Ò©Æ·ÐÅÏ¢ ÒÑÓÐ3È˲ÎÓë
|
|
Ò©ÎïËù´¦µÄ¿ª·¢½×¶Î£¿ ÇëÎÊÕâЩ·Ö±ðָʲô½×¶Î£¿¶¼ÊÇÄÄЩӢÎĵÄËõд£¿PC I II III PA A M PM D F NA I II III ²»ÓÃ˵ÁË ÊÇÖ¸²»Í¬µÄÁÙ´²½×¶Î PCÊDz»ÊÇÖ¸ÁÙ´²Ç°£¬PAÅú׼ǰ A Åú×¼ ¡¡ |
» ²ÂÄãϲ»¶
͸Ã÷ÖÊËá ¼×»ù±ûÏ©Ëáôû
ÒѾÓÐ0È˻ظ´
305²ÄÁÏר˶µ÷¼Á
ÒѾÓÐ12È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ140È˻ظ´
¹ØÓÚSCIÔÓÖ¾·¢±í¹ÒÃû
ÒѾÓÐ32È˻ظ´
CSC¸ÄÅÉ-²©Ê¿Éú½»Á÷·Ãѧ
ÒѾÓÐ19È˻ظ´
ÖÐɽ´óѧ-µÚÆßÒ½Ôº-ÕпÆÑÐÖúÀí1Ãû£¨»ùÒòÉè¼ÆºÍ¿Ë¡¡¢RNAºÏ³É£©
ÒѾÓÐ0È˻ظ´
ÖÐɽ´óѧ-µÚÆßÒ½Ôº-ÕпÆÑÐÖúÀí1Ãû£¨»ùÒòÉè¼ÆºÍ¿Ë¡¡¢RNAºÏ³É£©
ÒѾÓÐ1È˻ظ´
°ÍÀèÈø¿ËÀ×´óѧÓë¹ú¼ÒÁôѧ»ù½ðίºÏ×÷²©Ê¿Ñо¿ÉúÏîÄ¿-Ö¬ÖÊÄÉÃ×Ò©Îï/ÉúÎï²ÄÁÏ/¶à·ÓµÝËÍ
ÒѾÓÐ10È˻ظ´
292ҩѧµ÷¼Á
ÒѾÓÐ1È˻ظ´
½õÖÝÒ½¿Æ´óѧҩÓÃÉúÎï²ÄÁÏ£¨×¨Òµ´úÂë1007Z1£©ÕÐÊÕµ÷¼Á¿¼Éú
ÒѾÓÐ0È˻ظ´
½õÖÝÒ½¿Æ´óѧҩÓÃÉúÎï²ÄÁÏ£¨×¨Òµ´úÂë1007Z1£©ÕÐÊÕµ÷¼Á¿¼Éú
ÒѾÓÐ1È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
ÇëÎÊÔõôÔÚFDAÍøÕ¾ÉϲéÒ»¸öÒ©Îï±»Åú×¼µÄʱ¼ä°¡£¬»òÕßÖªµÀËü...
ÒѾÓÐ14È˻ظ´
ÊÇ·ñÒÔºó1.1Àà´´ÐÂÒ©µÄINDÉêÇë²»ÐèÒªÉóÅúÁË£¿¸úÃÀ¹úFDAÒ»Ñù£¿
ÒѾÓÐ11È˻ظ´
¶ÔÓÚ²éѯҩƷÔÑг§¼ÒµÄ·½·¨
ÒѾÓÐ3È˻ظ´
FDA֪ʶ ÓÐÓÃÒ»¶¨×·¼Ó½ð±Ò
ÒѾÓÐ4È˻ظ´
¡¾×ªÌû¡¿Ò©Æ·²éÑ¯ÍøµÄÊý¾Ý¿â
ÒѾÓÐ77È˻ظ´
¡¾ÇóÖú¡¿Ò©Æ·DMF±àд
ÒѾÓÐ9È˻ظ´
¡¾ÌÖÂÛ¡¿Çë½ÌÈçºÎÀûÓÃFDA²éѯҩƷÐÅÏ¢
ÒѾÓÐ9È˻ظ´
¡¾ÇóÖú¡¿ÈçºÎ²éѯҩƷÕýÔÚÉ걨µÄ³§¼ÒÇé¿ö
ÒѾÓÐ7È˻ظ´
¡¾ÇóÖú¡¿¹úÍâÉÏÊÐÒ©Æ·µÄÐÅÏ¢
ÒѾÓÐ14È˻ظ´
¡¾ÇóÖú¡¿ÈçºÎ²éѯÐÂÒ©µÄ¹úÍâ×ÊÁÏ
ÒѾÓÐ17È˻ظ´
maryray
ͳæ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 91.5
- Ìû×Ó: 5
- ÔÚÏß: 2.2Сʱ
- ³æºÅ: 1101517
- ×¢²á: 2010-09-17
- ÐÔ±ð: GG
- רҵ: Ò©Îï·ÖÎö
2Â¥2010-09-26 15:32:09
iamzane
ÖÁ×ðľ³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 129 (¸ßÖÐÉú)
- ¹ó±ö: 0.7
- ½ð±Ò: 24628.1
- É¢½ð: 40
- ºì»¨: 21
- Ìû×Ó: 1974
- ÔÚÏß: 459.5Сʱ
- ³æºÅ: 330866
- ×¢²á: 2007-03-24
- רҵ: Ò©ÎïѧÆäËû¿ÆÑ§ÎÊÌâ
¡ï ¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
koria0727(½ð±Ò+1):¶àл²ÎÓë¡£ 2010-09-26 16:53:30
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
koria0727(½ð±Ò+1):¶àл²ÎÓë¡£ 2010-09-26 16:53:30
|
PC preclinical PA product application A approved M market PM post market ºóÃæ¼¸¸ö¾Í²»ÖªµÀÁË |
3Â¥2010-09-26 16:39:44
9123pharma
Ìú³æ (СÓÐÃûÆø)
- Ó¦Öú: 2 (Ó×¶ùÔ°)
- ½ð±Ò: 104.6
- ºì»¨: 1
- Ìû×Ó: 109
- ÔÚÏß: 24.3Сʱ
- ³æºÅ: 1000854
- ×¢²á: 2010-04-19
- רҵ: ÉúÎïÒ½Ò©/Ò½Ò©Êг¡
¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
|
½Ó2Â¥µÄ D Discontinued NA Not Approved F²»Çå³þָʲô |

4Â¥2010-09-30 16:36:52
maryray
ͳæ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 91.5
- Ìû×Ó: 5
- ÔÚÏß: 2.2Сʱ
- ³æºÅ: 1101517
- ×¢²á: 2010-09-17
- ÐÔ±ð: GG
- רҵ: Ò©Îï·ÖÎö
¡ï
warlen(½ð±Ò+1): лл²ÎÓë 2011-08-05 10:07:02
warlen(½ð±Ò+1): лл²ÎÓë 2011-08-05 10:07:02
|
PC-- Pre Clinical I-- Phase one II-- Phase two III-- Phase three PA-- Pending Approval A-- Approved M-- On the Market PM-- Post Marketing Trials D-- Discontinued F-- Failed Total Trials NA-- No Details found (or) At Research Stage |
5Â¥2011-08-05 09:51:55













»Ø¸´´ËÂ¥